Since then, HER‐2 was considered as a significant targeted point due to its distinctive role in tumour cell proliferation and metastasis, facilitating the development of HER‐2 targeted agents, which have shown a tremendous success 91. This evidence concerns the gene ERBB2 and neoplasm.